This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Myomo, Inc. (MYO) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Myomo, Inc. (MYO) delivered earnings and revenue surprises of -40% and 1.19%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
What Makes Myomo, Inc. (MYO) a Good Fit for 'Trend Investing'
by Zacks Equity Research
If you are looking for stocks that are well positioned to maintain their recent uptrend, Myomo, Inc. (MYO) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Myomo, Inc. (MYO) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Myomo, Inc. (MYO) delivered earnings and revenue surprises of 0% and 3.73%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Myomo's (MYO) MyoPro Seeks CMS Classification for Medicare Cover
by Zacks Equity Research
If this rule is finalized without any changes to reimbursement practices, Myomo's (MYO) MyoPro could be reimbursed in a lump-sum manner by CMS.
Here's Why Myomo, Inc. (MYO) Is a Great 'Buy the Bottom' Stock Now
by Zacks Equity Research
Myomo, Inc. (MYO) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Myomo, Inc. (MYO) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Myomo, Inc. (MYO) delivered earnings and revenue surprises of 26.67% and 3.51%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Supernus Pharmaceuticals (SUPN) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Supernus (SUPN) delivered earnings and revenue surprises of 141.67% and 8.99%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Owens & Minor (OMI) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Owens & Minor (OMI) delivered earnings and revenue surprises of 155.56% and 4.15%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Myomo, Inc. (MYO) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Myomo, Inc. (MYO) delivered earnings and revenue surprises of 34.09% and 0.45%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Vapotherm (VAPO) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Vapotherm (VAPO) delivered earnings and revenue surprises of 6.33% and 0.58%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Myomo, Inc. (MYO) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Myomo, Inc. (MYO) delivered earnings and revenue surprises of 14.89% and 4.70%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
NuVasive (NUVA) Surpasses Q3 Earnings Estimates
by Zacks Equity Research
NuVasive (NUVA) delivered earnings and revenue surprises of 1.89% and 0.80%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
OraSure Technologies (OSUR) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
OraSure (OSUR) delivered earnings and revenue surprises of 216.67% and 26.42%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Myomo, Inc. (MYO) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Myomo, Inc. (MYO) delivered earnings and revenue surprises of 6.67% and 4.79%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Maravai LifeSciences Holdings, Inc. (MRVI) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Maravai LifeSciences Holdings, Inc. (MRVI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Stryker's (SYK) Q2 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Stryker's (SYK) second-quarter earnings reflect strong performance across its segments. However, unfavorable currency movement hurt sales growth.
What Makes Myomo, Inc. (MYO) a New Strong Buy Stock
by Zacks Equity Research
Myomo, Inc. (MYO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Myomo, Inc. (MYO) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Myomo, Inc. (MYO) delivered earnings and revenue surprises of 24.07% and 35.72%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
ICU Medical (ICUI) Surpasses Q1 Earnings Estimates
by Zacks Equity Research
ICU Medical (ICUI) delivered earnings and revenue surprises of 1.68% and 0.67%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Myomo, Inc. (MYO) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Myomo, Inc. (MYO) delivered earnings and revenue surprises of -6.12% and 34.36%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Insulet (PODD) Tops Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Insulet (PODD) delivered earnings and revenue surprises of 40% and 2.30%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Myomo, Inc. (MYO) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Myomo, Inc. (MYO) delivered earnings and revenue surprises of 23.40% and 40.06%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Will Myomo, Inc. (MYO) Report Negative Q3 Earnings? What You Should Know
by Zacks Equity Research
Myomo, Inc. (MYO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Myomo, Inc. (MYO) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Myomo, Inc. (MYO) delivered earnings and revenue surprises of 25.81% and 51.86%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Myomo, Inc. (MYO) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
by Zacks Equity Research
Myomo, Inc. (MYO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.